EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours

Rafael Zago Baltazar, Sofie Claerhout iD, Sara Vander Borght, Lien Spans, Raphael Sciot, Patrick Schöffski, Daphne Hompes, Friedl Sinnaeve, Hazem Wafa, Marleen Renard, Mari Fcm van den Hout, Astrid Vernemmen und 7 weitere

The Journal of Pathology: Clinical Research · 2024

DOI: 10.1002/2056-4538.12376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology: Clinical Research, 2024. Verfasst von Rafael Zago Baltazar und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Human Genetics, University Hospitals KU Leuven, Leuven, Belgium. Hauptthemen laut MEDLINE: Bone Neoplasms, Soft Tissue Neoplasms, Workflow, In Situ Hybridization, Fluorescence. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Universitaire Ziekenhuizen Leuven, KU Leuven.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The identification of gene fusions has become an integral part of soft tissue and bone tumour diagnosis. We investigated the added value of targeted RNA‐based sequencing (targeted RNA‐seq, Archer FusionPlex) to our current molecular diagnostic workflow of these tumours, which is based on fluorescence in situ hybridisation (FISH) for the detection of gene fusions using 25 probes. In a series of 131 diagnostic samples targeted RNA‐seq identified a gene fusion, BCOR internal tandem duplication or ALK deletion in 47 cases (35.9%). For 74 cases, encompassing 137 FISH analyses, concordance between FISH and targeted RNA‐seq was evaluated. A positive or negative FISH result was confirmed by targeted RNA‐seq in 27 out of 49 (55.1%) and 81 out of 88 (92.0%) analyses, respectively. While negative concordance was high, targeted RNA‐seq identified a canonical gene fusion in seven cases despite a negative FISH result. The 22 discordant FISH‐positive analyses showed a lower percentage of rearrangement‐positive nuclei (range 15–41%) compared to the concordant FISH‐positive analyses (>41% of nuclei in 88.9% of cases). Six FISH analyses (in four cases) were finally considered false positive based on histological and targeted RNA‐seq findings. For the EWSR1 FISH probe, we observed a gene‐dependent disparity ( p = 0.0020), with 8 out of 35 cases showing a discordance between FISH and targeted RNA‐seq (22.9%). This study demonstrates an added value of targeted RNA‐seq to our current diagnostic workflow of soft tissue and bone tumours in 19 out of 131 cases (14.5%), which we categorised as altered diagnosis (3 cases), added precision (6 cases), or augmented spectrum (10 cases). In the latter subgroup, four novel fusion transcripts were found for which the clinical relevance remains unclear: NAB2::NCOA2 , YAP1::NUTM2B , HSPA8::BRAF , and PDE2A::PLAG1 . Overall, targeted RNA‐seq has proven extremely valuable in the diagnostic workflow of soft tissue and bone tumours.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone NeoplasmsSoft Tissue NeoplasmsWorkflowIn Situ Hybridization, FluorescenceHumansFemaleAdultMaleMiddle AgedAdolescentAgedSequence Analysis, RNAChildYoung AdultGene FusionBiomarkers, TumorChild, PreschoolAged, 80 and overOncogene Proteins, Fusion

Stichwörter der Autor:innen

FISHRNA‐seqbone tumourssarcomassoft tissue tumours

Substanzen

Biomarkers, TumorOncogene Proteins, Fusion

Autor:innen und Institutionen

  • Department of Human Genetics, University Hospitals KU Leuven, Leuven, Belgium.
  • Department of Pathology, University Hospitals KU Leuven, Leuven, Belgium.
  • Department of General Medical Oncology, University Hospitals KU Leuven, Leuven, Belgium.
  • Department of Surgical Oncology, University Hospitals KU Leuven, Leuven, Belgium.
  • Department of Orthopaedic Surgery, University Hospitals KU Leuven, Leuven, Belgium.
  • Department of Paediatric Hemato-Oncology, University Hospitals KU Leuven, Leuven, Belgium.

ORCID-Profile: Sofie Claerhout, Isabelle Vanden Bempt

Förderung

  • Universitaire Ziekenhuizen Leuven, KU Leuven

Zitieren

APA

Zago Baltazar, R., Claerhout, S., Vander Borght, S., Spans, L., Sciot, R., Schöffski, P., Hompes, D., Sinnaeve, F., Wafa, H., Renard, M., van den Hout, M. F., Vernemmen, A., Libbrecht, L., De Roo, A. K., Mazzeo, F., van Marcke, C., Deraedt, K., Bourgain, C., & Vanden Bempt, I. (2024). Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours. The Journal of Pathology: Clinical Research. https://doi.org/10.1002/2056-4538.12376

Vancouver

Zago Baltazar R, Claerhout S, Vander Borght S, Spans L, Sciot R, Schöffski P, et al. Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours. The Journal of Pathology: Clinical Research. 2024. doi:10.1002/2056-4538.12376

BibTeX
@article{ZagoBaltazar2024,
  author = {Zago Baltazar, Rafael and Claerhout, Sofie and Vander Borght, Sara and Spans, Lien and Sciot, Raphael and Schöffski, Patrick and Hompes, Daphne and Sinnaeve, Friedl and Wafa, Hazem and Renard, Marleen and van den Hout, Mari Fcm and Vernemmen, Astrid and Libbrecht, Louis and De Roo, An-Katrien and Mazzeo, Filomena and van Marcke, Cédric and Deraedt, Karen and Bourgain, Claire and Vanden Bempt, Isabelle},
  title = {Recurrent and novel fusions detected by targeted RNA sequencing as part of the diagnostic workflow of soft tissue and bone tumours},
  journal = {The Journal of Pathology: Clinical Research},
  year = {2024},
  doi = {10.1002/2056-4538.12376}
}
Kostenlos starten →